MAIL ONLINE: Amgen drug extends survival in some inoperable colon cancers
Press/Media: Research
Media coverage
| Title | Amgen drug extends survival in some inoperable colon cancers |
|---|---|
| Media name/outlet | Mail Online |
| Media type | Web |
| Country/Territory | United Kingdom |
| Date | 5/06/22 |
| Description | June 5 (Reuters) - The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Amgen drug extends survival for some advanced colon cancers Amgen Inc's drug Vectibix led to "the longest survival ever reported" in a major trial for patients with inoperable advanced cancer originating on the left side of the colon whose tumors did not have RAS gene mutations, researchers reported on Sunday at ASCO 2022 https://meetings.asco.org/2022-asco-annual-meeting/14416?presentation=208990#208990. Amgen's monoclonal antibody, known chemically as panitumumab, belongs to a class of drugs called EGFR inhibitors. The standard treatment in many countries, however, is an anti-VEGF antibody like Roche's Avastin, which means many patients with inoperable metastatic cancer may not have been getting the most effective treatment. https://www.ibtimes.com/amgen-drug-extends-survival-some-inoperable-colon-cancers-3530544 https://www.usnews.com/news/top-news/articles/2022-06-05/amgen-drug-extends-survival-in-some-inoperable-colon-cancers |
| URL | https://www.dailymail.co.uk/wires/reuters/article-10886525/CANCER-RESEARCH-Amgen-drug-extends-survival-inoperable-colon-cancers.html |
| Persons | Martin Mccabe |